DPP4 and colorectal carcinoma: Results were still very encouraging for the CRC cohort with patients treated with DPP4 inhibitors showing a positive trend in improved survival but not meeting statistically significant threshold with HR of 0.87 (95% CI: 0.75‐1.00, P = 0.055).